ConCallIQ
Go Pro
ANLONHEALTHCARE Healthcare 15 Feb 2026

Anlon Healthcare Ltd — Q3 FY26

Anlon Healthcare delivered a stellar Q3 FY26 with revenue surging to ₹35.78 Cr (up 281% YoY) and EBITDA margin of 35.06%, driven by higher API and intermediate volumes, operatin...

bullish high
Compare with...
Revenue ₹36 Cr +281.45%
EBITDA ₹13 Cr
PAT ₹5 Cr
EBITDA Margin 35.06%
Duration 52 min
Read Time 1 min read

Financial stats pending filing verification

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

High Working Capital Days

Receivable days are currently ~290 days, posing cash flow risk. Management targets reduction to 150-160 days by FY27, but execution is uncertain.

high · analyst_question
R

Integration and Execution Risk from Acquisitions

Acquisitions of Epico and Bizotic require smooth integration; any delays or operational issues could impact revenue and margin targets.

medium · management_commentary
R

Customer Concentration in NSAID Segment

~30-35% revenue from loxoprofen and ketoprofen; any demand shock or regulatory issue in this segment could materially affect results.

medium · analyst_question
R

Capacity Constraints Before Greenfield Completion

Existing facilities are near full utilization; until greenfield expansion is operational (by March 2027), growth may be constrained.

medium · data_observation